FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features
about
Ameloblastoma: A Review of Recent Molecular Pathogenetic DiscoveriesFibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implicationsGenomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumorsIntegrated genomic characterization of endometrial carcinomaFGF receptors: cancer biology and therapeuticsEmergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumoursIn-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor.Yes-associated protein (YAP) modulates oncogenic features and radiation sensitivity in endometrial cancerEpithelial-to-Mesenchymal Transition in the Female Reproductive Tract: From Normal Functioning to Disease Pathology.The emerging genomic landscape of endometrial cancer.Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles.Prognostic significance of mucinous differentiation of endometrioid adenocarcinoma of the endometrium.High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutatedA phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer.Molecular staging of gynecological cancer: What is the future?Expression of fibroblast growth factor receptor family members is associated with prognosis in early stage cervical cancer patientsFGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.Glycogen synthase kinase 3β inhibition as a therapeutic approach in the treatment of endometrial cancer.An update of the classical Bokhman's dualistic model of endometrial cancer.FGFR1, 2 and 3 protein overexpression and molecular aberrations of FGFR3 in early stage non-small cell lung cancer.Use of mutation profiles to refine the classification of endometrial carcinomas.Prognostic biomarkers in endometrial and ovarian carcinoma.Current status of molecular biomarkers in endometrial cancer.Novel targets for the treatment of ameloblastoma.Malignant tumors of the uterine corpus: molecular background of their origin.FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.FGFR2 regulates Mre11 expression and double-strand break repair via the MEK-ERK-POU1F1 pathway in breast tumorigenesis.The future role of molecular staging in gynecologic cancer.Endometrial Carcinoma: Specific Targeted Pathways.Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity.Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.Fibroblast growth factor-mediated crosstalk in cancer etiology and treatment.Clinical significance of fibroblast growth factor receptor 2 expression in patients with residual rectal cancer after preoperative chemoradiotherapy: relationship with KRAS or BRAF mutations and MSI status.CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence.Endometrial Cancer-Associated FGF18 Expression Is Reduced by Bazedoxifene in Human Endometrial Stromal Cells In Vitro and in Murine Endometrium.Association of body mass index with ER, PR and 14-3-3σ expression in tumor and stroma of type I and type II endometrial carcinoma.Fibroblast Growth Factor Receptor 2 Signaling in Breast Cancer.Endometrial Cancers Harboring Mutated Fibroblast Growth Factor Receptor 2 Protein Are Successfully Treated With a New Small Tyrosine Kinase Inhibitor in an Orthotopic Mouse Model.
P2860
Q26781648-AAF992BF-F3A6-437F-9F3A-EBC609DCDC6FQ26801718-6FEA0675-2BEC-46D0-A1AF-FDE1BCBFAEDEQ26998790-A005991F-02A7-41CE-A714-548C9A9F40B4Q28289962-78DE3231-713C-4BD1-8E8F-09F634FE6F0CQ28291186-F7236BEB-9FCB-4C59-B2C9-304FAEDB0807Q28609639-318473BD-ABEE-4E0D-AEC9-34E15979F8F7Q33601377-DEF68BC9-75AC-4EC9-A833-4DC359664F27Q33817465-66FBE1E5-FECC-43D9-9922-0E063AF656F2Q33872622-4962DE0E-3C9C-4E04-A80C-FE43D4B884E2Q34026976-D69B3C34-B1DC-459B-826F-72658D82FA8FQ34350701-FDF8EB8C-E211-4789-8FFD-B648EA148FAAQ34504603-CF51A4F6-12A6-4515-A37E-C1A6A3984ABEQ34541232-F433F869-97A2-4976-B164-F94B117B894EQ34781699-00EB90E1-1CB9-41EF-93A5-9907D082A680Q35691011-845EEEDC-9FA0-4AC4-AD6A-17D1B5EC7217Q35940829-3C9CC2BE-76D3-4173-9EFB-B376D0E34854Q36879739-2DFA9CFC-A6C2-4E93-9886-E638CB4F8D09Q36983860-B9227EFC-2A69-43AB-8259-95A6A6A25EFDQ37061044-8B31C049-1DAA-4CA5-AF5D-1B80528319CDQ37139199-36F5D2AC-4154-44BC-BC68-6A3AA2DAE7E9Q37195410-B6FA8B5B-599D-453B-8C23-5D13001FBD6AQ37346563-14FD21EB-F81A-4D32-97C9-4B60F1281014Q37612253-67678A97-5090-48BB-86BC-6969A727E42FQ38185940-FB1BF7C9-2F98-4698-B506-6ABA0264BD11Q38234228-717F5A10-F274-49A6-BFAB-E94DE427496AQ38271523-D1483076-D5B7-4A0C-AEC5-726A76105679Q38573869-8B78DCB7-5F9A-42A3-BC63-B9BDC9DD6E66Q38897134-4D027672-0E1E-4EC0-BD1D-D8FBC44F01EBQ38897689-5084D035-215A-4380-945B-6C5041AAD1FFQ38957038-F2B956CC-174A-43DD-87AC-59655199F38FQ39026766-27390730-F5A3-4D92-B666-6348CE15399DQ39062384-9358C240-1A1C-42FF-B33E-FD2A125F86D7Q39184115-8182A5EE-70F8-4DCE-897F-62D4CB3C9C0FQ39282670-5B8B3BB0-B89E-4CB7-B248-BD38DB3BAF82Q40036023-31814095-D67D-4211-A759-DBE00D3C5215Q40986278-67A0BD9D-C558-4733-97BE-B444D7F21940Q41640781-322E13A6-43FE-4E23-81E8-E89053D626CFQ41975494-57718755-B100-47E0-BC19-FE68277E95D6Q44643445-EB56E8E5-5953-429E-ACB8-AD65EF22FFA7Q47736935-06F5009E-0957-47F3-9C98-9151B1CEC58E
P2860
FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
FGFR2 point mutations in 466 e ...... d clinicopathological features
@ast
FGFR2 point mutations in 466 e ...... d clinicopathological features
@en
FGFR2 point mutations in 466 e ...... d clinicopathological features
@nl
type
label
FGFR2 point mutations in 466 e ...... d clinicopathological features
@ast
FGFR2 point mutations in 466 e ...... d clinicopathological features
@en
FGFR2 point mutations in 466 e ...... d clinicopathological features
@nl
prefLabel
FGFR2 point mutations in 466 e ...... d clinicopathological features
@ast
FGFR2 point mutations in 466 e ...... d clinicopathological features
@en
FGFR2 point mutations in 466 e ...... d clinicopathological features
@nl
P2093
P2860
P50
P3181
P1433
P1476
FGFR2 point mutations in 466 e ...... d clinicopathological features
@en
P2093
Candice L Wellens
David G Mutch
Matthew A Powell
Michael Gartside
Paul J Goodfellow
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0030801
P407
P577
2012-01-01T00:00:00Z